Patents Examined by Michael G. Hartley
  • Patent number: 10597409
    Abstract: The invention relates to complexing agents of formula (I) in which A1, A2, A3 and R1 are as defined in the description. The invention also relates to lanthanide complexes obtained from said complexing agents. The invention can be used for marking biological molecules.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: March 24, 2020
    Inventors: Laurent Lamarque, Claude Picard, Chantal Galaup, Nadine Leygue, Jurriaan Zwier, Emmanuel Bourrier
  • Patent number: 10596269
    Abstract: The teachings provide methods of delivering active agents that are conjugated with delivery systems that increase the half-life, and reduce the immunogenicity, of the active agents. Delivery systems and methods of making and using the delivery systems are also provided. The delivery systems have (i) a ligand that is selective for an endogeneous plasma protein in the serum of a subject; and, (ii) a linker configured for operatively attaching the ligand covalently to an active agent to increase the half-life of the active agent in the serum.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: March 24, 2020
    Inventor: Mamoun M Alhamadsheh
  • Patent number: 10596276
    Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: March 24, 2020
    Inventors: Francesco de Palo, Lorenza Fugazza, Donato Barbato, Maurizio Mariani, Daniela Chicco, Giovanni Tesoriere, Clementina Brambati
  • Patent number: 10597340
    Abstract: Provided herein are methods and compositions for the electrochemical selective radiofluorination of aromatic molecules. The resulting fluorine-18 labeled compounds are ideal radionuclides for use in Positron Emission Tomography (PET); they are also difficult to radiolabel efficiently and with high specific activity using existing approaches. For example, radiopharmaceuticals such as [F18]L-DOPA, which is indispensable in PET brain disease imaging, may be made electrochemically with high radiochemical yield and high specific activity using 18F-. The invention process described herein opens new possibilities and provides wider access to PET tracers such as 18F-L-Dopa, since 18F- is much more widely available than the 18F2, currently used for synthesis of electron rich substrates.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: March 24, 2020
    Inventors: Saman Sadeghi, Qinggang He, Artem Lebedev
  • Patent number: 10596277
    Abstract: This invention relates to radioactive, bone-seeking, pharmaceutical methods, compositions and formulations that have a lower impurity profile, a longer shelf life, improved availability and are less expensive to prepare. The compositions of this invention can be conveniently prepared in a timely manner resulting in improved availability and delivery of the drugs to patients.
    Type: Grant
    Filed: November 17, 2018
    Date of Patent: March 24, 2020
    Assignee: IGL Pharma, Inc.
    Inventors: Jaime Simon, R. Keith Frank, David A. Wilson
  • Patent number: 10588972
    Abstract: The present invention relates to compositions and methods for destroying target cells in a patient using photodynamic therapy. In particular, the present invention provides a photosensitizing agent based on a small molecular weight (<50 kDa) protein or peptide or a small molecule that is conjugated to a phthalocyanine dye, such as IRDye® 700DX.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 17, 2020
    Assignee: LI-COR, INC.
    Inventor: Joy L. Kovar
  • Patent number: 10583206
    Abstract: Provided is a probe for detecting in vivo hydrogen sulfide, specifically, a probe for detecting hydrogen sulfide including a complex compound into which a radioactive isotope Cu is introduced. According to specific embodiments of the present disclosure, as a result of real-time observing animal models, in which hydrogen sulfide involved in various diseases is generated in a large quantity, through optical and nuclear medicine imaging, the probe for detecting hydrogen sulfide according to the present disclosure may selectively bind with hydrogen sulfide to provide images of a site where hydrogen sulfide has abnormally increased in a cell or a tissue, thereby detecting a disease in an unexpected site without affecting the anatomical properties of the body. Accordingly, the probe may be effectively used as a means for diagnosing diseases, such as a composition for imaging, an imaging method, etc.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: March 10, 2020
    Assignee: Kyungpook National University Industry-Academic, Cooperation Foundation
    Inventors: Jeong Soo Yoo, Swarbhanu Sarkar, Yeong Su Ha, Woong Hee Lee
  • Patent number: 10583209
    Abstract: 1-13C-1,1-Bis(acetoxy(methyl))-2,2?-cyclopropane of formula (I): The compound can be hyperpolarized and used as a contrast agent in 13C Magnetic Resonance diagnostic technique (13C-MR) for the diagnosis of tumor.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: March 10, 2020
    Assignee: BRACCO IMAGING S.P.A.
    Inventors: Mathilde H. Lerche, Pernille Rose Jensen, Magnus Karlsson, Roberta Napolitano, Claudia Cabella, Luigi Miragoli, Sonia Colombo Serra, Fabio Tedoldi
  • Patent number: 10583210
    Abstract: A method is provided for treating or ameliorating a high-grade glioma in a patient, which method comprises intracerebral administering of a radioactive agent characterized by a short-range cytotoxic ionizing radiation by convection-enhanced delivery. Further, a radioactive agent characterized by a short-range cytotoxic ionizing radiation is provided for use in treating or ameliorating a high-grade glioma, where the agent is administered by intracerebral convection-enhanced delivery.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: March 10, 2020
    Assignees: Syddansk Universitet, Region Syddanmark
    Inventors: Helge Thisgaard, Bo Halle, Poul Flemming Høilund-Carlsen, Bjarne Winther Kristensen, Charlotte Aaberg-Jessen
  • Patent number: 10583211
    Abstract: This invention concerns a pharmaceutically-acceptable composition of radioactive metals, which are used for treating various diseases in animals or humans, such as cancer and arthritis.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: March 10, 2020
    Assignee: IsoTherapeutics Group LLC
    Inventors: David A Wilson, R. Keith Frank, Jaime Simon, Druce K Crump
  • Patent number: 10568970
    Abstract: Provided herein are theranostic compositions comprising a Janus nanoparticle-coated microbubble that are useful for imaging (e.g., MRI, or ultrasound) and for delivering a therapeutic or bioactive agent (e.g., nucleic acid(s), drugs, etc), among other uses.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: February 25, 2020
    Inventors: Joyce Y. Wong, Ragnhild D. Whitaker, Nelson Ruiz-Opazo, Victoria L. M. Herrera
  • Patent number: 10568831
    Abstract: An edible composition of matter having an apparent viscosity of from about 150 cP to about 2000 cP at about 30 s?1; a yield stress of from 0 Pa to about 20 Pa at 1 s?1; and a flow index of from about 0.2 to about 0.6. The composition may include an imaging agent. The compositions are useful for providing sustenance to dysphagic subjects and for evalualuating dysphagia.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 25, 2020
    Assignees: Wisconsin Alumni Research Foundation, The Regents of the University of Minnesota
    Inventors: Heather N. Mendenhall, Richard W. Hartel, JoAnne Robbins, Jacqueline A. Hind, Zata M. Vickers
  • Patent number: 10568978
    Abstract: The invention relates to products and methods that provide increased yields of certain radiopharmaceuticals.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: February 25, 2020
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, James F. Castner
  • Patent number: 10561745
    Abstract: Materials and methods for synthesizing magnetic core/gold shell nanoparticles and magneto-plasmonic nanostars are provided. Formulations comprising nanoparticles optionally bound to or co-loaded with a therapeutic agent encapsulated within liposomes are provided. A method for treating diseases (e.g., brain diseases) in a subject by administering to the subject a formulation comprising the nanoparticle formulation is also provided. Further, a method is provided for imaging a target site of a subject following the administering of the nanoparticle formulations.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: February 18, 2020
    Inventors: Asahi Tomitaka, Madhavan Nair
  • Patent number: 10562835
    Abstract: Disclosed herein are embodiments of a method for producing thorium-226. The method comprises separating thorium-226 from uranium-230 to produce a solution of thorium-226 in a solvent, such as a chelating buffer, suitable for direct labeling by a chelate. The thorium-226 may be separated from the uranium-230 using extraction chromatography. The extraction may be repeated multiple times as additional thorium-226 is produced by uranium-230 decay.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: February 18, 2020
    Assignee: Triad National Security, LLC
    Inventors: Michael E. Fassbender, Tara E. Mastren
  • Patent number: 10562920
    Abstract: The present invention concerns heterometallic metallacrown compounds incorporating Ga(III) and Ln(III) cations, with a templating ligand such as salicylhydroxamic acid or derivatives thereof, wherein said metallacrown contains at least one repeating [—Ga—N—O—] sub-unit where the N—O derives from the templating ligand.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: February 18, 2020
    Inventors: Evan R. Trivedi, Vincent L. Pecoraro, Svetlana V. Eliseeva, Stépane Petoud, Chun Y. Chow, Tu Ngoc Nguyen, Jacob Charles Lutter, Ivana Martinic
  • Patent number: 10561748
    Abstract: The present invention is directed to a novel compound of Formula 1 wherein the radiolabeled compound of Formula 1 is capable of being used as a radiotracer in PET imaging of a targeted localized tissue and targeted radionuclide therapy of one or more conditions that may be regulated or normalized via inhibition of transporter such as Pgp, BCRP or MRP I. The novel compounds of Formula 1 can also be used as substrates for binding with one or more ABC transporters. In particular, the present invention aids in diagnosis and therapeutic treatment of MDR disorders in all forms of cancers and neurological disorders of the central nervous system. The present invention further provides methods of preparation of compounds of Formula 1 and novel intermediates used in the preparation of compounds of Formula 1.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: February 18, 2020
    Inventor: Divya Maheshwari
  • Patent number: 10556023
    Abstract: Fluoridated organofluoroborates comprising at least one 18F atom and precursors thereto, for use in PET scanning.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: February 11, 2020
    Inventors: David Perrin, Zhibo Liu
  • Patent number: 10556916
    Abstract: The invention provides a method of preparing a 89Zr-oxine complex of the formula. The invention also provides a method of labeling a cell with the 89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the 89Zr-oxine complex to the subject.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: February 11, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Noriko Sato, Haitao Wu, Gary L. Griffiths, Peter L. Choyke
  • Patent number: 10555544
    Abstract: This invention provides edible compositions comprising pharmaceutically or nutraceutically active agents in particulate form homogeneously dispersed in a fat matrix, such as chocolate or chocolate compound coating.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: February 11, 2020
    Assignee: Lesaffre Yeast Corporation
    Inventor: Kevin W. Lang